Investigation Launched Against Viatris Inc. over Alleged Securities Law Violations
New York, NY – March 30, 2025:
Levi & Korsinsky, a leading securities law firm, has announced the commencement of an investigation into Viatris Inc. (NASDAQ: VTRS) over potential securities law violations. The investigation follows Viatris’ February 27, 2025, press release detailing its fourth quarter and full year 2024 financial results.
Fourth Quarter and Full Year 2024 Financial Results
Viatris reported a net loss of $1.1 billion for the fourth quarter, significantly wider than the consensus estimate of a $707 million loss. The company’s revenue for the quarter came in at $4.6 billion, below the consensus estimate of $4.7 billion. For the full year 2024, Viatris reported a net loss of $3.5 billion and revenue of $17.2 billion, both missing the consensus estimates.
Impact on Viatris and Shareholders
The financial miss raised concerns among investors, leading to a significant drop in Viatris’ stock price. Following the earnings report, Viatris’ shares fell by more than 20% in after-hours trading. The Securities and Exchange Commission (SEC) and other regulatory bodies will be examining Viatris’ disclosures and financial reporting processes to determine if any securities laws were violated.
Effect on Individual Investors
- Investors who purchased Viatris shares prior to the earnings report may be able to recover their losses through a securities class action lawsuit.
- Individual investors are encouraged to contact Levi & Korsinsky to discuss their potential participation in the investigation.
Impact on the World
The investigation into Viatris could have far-reaching consequences, as it highlights the importance of accurate financial reporting and the potential consequences of failing to meet expectations. This incident serves as a reminder for companies to prioritize transparency and honesty in their financial reporting to maintain investor confidence and trust.
Conclusion
Levi & Korsinsky’s investigation into Viatris Inc. comes in response to the pharmaceutical company’s disappointing fourth quarter and full year 2024 financial results. The potential securities law violations could result in significant consequences for Viatris and its shareholders. As the investigation unfolds, it also serves as a reminder for companies to prioritize transparency and honesty in their financial reporting to maintain investor trust and confidence.
Individual investors who purchased Viatris shares prior to the earnings report are encouraged to contact Levi & Korsinsky to discuss their potential participation in the investigation. The investigation’s outcome could have far-reaching implications, emphasizing the importance of accurate financial reporting and the potential consequences of failing to meet expectations.
